AstraZeneca PLC

NYSE:AZN

Drug Manufacturers - General

Healthcare
$178.76 -1.71%

-$3.04 today

Market cap
$277.23B
Beta
0.21
P/E (TTM)
25.7
EPS (TTM)
$6.75
Dividend yield
1.80%
52W Low $137.22High $212.71

Volume 2.54M

Average 1.96M

AZN Income Tax Expense

Income taxes recognized for the period, including current and deferred tax.

AstraZeneca PLCNYSE: AZN

Income Tax Expense · Q3 FY2026 · quarter ended Sep 2026

Income tax expense growth accelerates

Q3 FY2026 income tax expense of $830.79M rose 17.2% year over year, ahead of the +10.8% change in trailing-twelve-month income tax expense. Sequentially, it rose 185.5% from the prior quarter.

Context

  • Income tax expense amounted to 3.7% of revenue in FY2025, up 0.6 pp from a year earlier.
  • Income tax expense increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +17.2% holds above the trailing-twelve-month pace of +10.8%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
$830.79M+185.5% QoQ
Last fiscal yearDec 2025
$2.17B+31.5% YoY
LTMSep 2026
$2.25B+10.8% YoY
Income Tax Expense past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+17.2%——
1 year+31.5%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Income Tax Expense history

USD · from the income statement

Latest · FY2025
2.17B USD
Year-over-year change
+31.5%

Income Tax Expense vs competitors

How AZN compares with its peers on the latest reported figures

  • Peers report in different currencies, so income tax expense is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +10.8% is the 7th highest of 10, against a peer median of +40.9%.
  • Income tax expense amounts to 3.6% of revenue for AZN, versus a peer median of 4.2%.
AZN Competitors
Income Tax Expense for AZN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NVONovo Nordisk A/SLTM Jun 2026DKK 32.31B DKK+8.7%+27.6%9.8%
LLYEli Lilly and CompanyLTM Jun 2026$6.88B USD+125.0%+108.5%8.6%
MRKMerck & Co., Inc.LTM Jun 2026$2.78B USD+1.3%+13.5%4.2%
NVSNovartis AGLTM Jun 2026$2.78B USD+40.9%+28.6%5.0%
BMYBristol-Myers Squibb CompanyLTM Jun 2026$2.63B USD+72.3%+18.4%5.4%
ABBVAbbVie Inc.LTM Sep 2026$2.47B USD+435.5%+13.1%3.7%
AZNAstraZeneca PLCLTM Sep 2026$2.25B USD+10.8%—3.6%
JNJJohnson & JohnsonLTM Sep 2026$1.64B USD-74.3%+24.6%1.7%
AMGNAmgen Inc.LTM Jun 2026$1.54B USD+91.8%+16.8%4.0%
PFEPfizer Inc.LTM Jun 2026-$164M USD+29.9%—0.3%
Peer median (excluding AZN) —+40.9%+21.5%4.2%

Competitors are the stored peer set for AZN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue37.42B44.35B45.81B54.07B58.74B
Cost of Revenue12.44B12.39B8.27B10.21B10.63B
Gross Profit24.98B31.96B37.54B43.87B48.11B
Gross Margin66.8%72.1%82.0%81.1%81.9%
Research & Development9.74B9.76B10.94B13.58B14.23B
Selling, General & Admin15.59B17.98B18.22B20.22B20.51B
Operating Expenses23.92B28.2B29.35B33.86B34.36B
Depreciation & Amortization4.1B5.25B4.93B5.07B5.73B
EBITDA5.11B9.09B13.42B15.44B19.83B
EBITDA Margin13.7%20.5%29.3%28.6%33.8%
Operating Income1.06B3.76B8.19B10B13.74B
Operating Margin2.8%8.5%17.9%18.5%23.4%
Interest Income43M81M301M345M360M
Interest Expense1.28B1.33B1.59B1.68B1.69B
Other Income / Expenses(1.32B)(1.26B)(1.29B)(1.31B)(1.34B)
Income Before Tax(265M)2.5B6.9B8.69B12.4B
Pre-Tax Margin-0.7%5.6%15.1%16.1%21.1%
Income Tax Expense(380M)(792M)938M1.65B2.17B
Net Income112M3.29B5.96B7.04B10.26B
Net Margin0.3%7.4%13.0%13.0%17.5%
EPS (Basic)0.082.123.814.546.60
EPS (Diluted)0.082.113.814.506.54
Weighted Avg Shares1.42B1.55B1.56B1.55B1.55B
Weighted Avg Shares (Diluted)1.43B1.56B1.56B1.56B1.56B

AstraZeneca PLC

NYSE:AZN

Intrinsic Alpha fair value

Locked

Current Price

$178.76

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.